Aptahem receives patent approval in India for patent family 1
Aptahem AB (publ) announce today that the company has received patent approval in India for patent family 1, with patent application number 6250/DELNP/2010. The patent, with the patent number 353024, covers the protection of the company’s aptamer structures.
The patent approval grants the company protection for Apta-1, Apta-2 and Apta-3 in India until 2029.
Similar patents have previously been approved in Europe, USA, Canada and China.
CEO Mikael Lindstam comments:
“We are delighted to announce that we now have received patent approval in the last country, India, for our patent application of patent family 1. With this approval, we have gained complete patent protection of our desired coverage of patent family 1, which strengthens Aptahem’s portfolio value.”
For further information:
Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com
About Aptahem
Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.